103 related articles for article (PubMed ID: 26066655)
21. Tetraspanin 8 (TSPAN 8) as a potential target for radio-immunotherapy of colorectal cancer.
Maisonial-Besset A; Witkowski T; Navarro-Teulon I; Berthier-Vergnes O; Fois G; Zhu Y; Besse S; Bawa O; Briat A; Quintana M; Pichard A; Bonnet M; Rubinstein E; Pouget JP; Opolon P; Maigne L; Miot-Noirault E; Chezal JM; Boucheix C; Degoul F
Oncotarget; 2017 Mar; 8(13):22034-22047. PubMed ID: 28423546
[TBL] [Abstract][Full Text] [Related]
22. Peptide aptamer identified by molecular docking targeting translationally controlled tumor protein in leukemia cells.
Kadioglu O; Efferth T
Invest New Drugs; 2016 Aug; 34(4):515-21. PubMed ID: 26972431
[TBL] [Abstract][Full Text] [Related]
23. Radioimmunotherapy of non-Hodgkin's lymphoma: molecular targeting and novel agents.
Pauwels EK; Erba P
Drug News Perspect; 2007 Mar; 20(2):87-93. PubMed ID: 17440631
[TBL] [Abstract][Full Text] [Related]
24. A review of monoclonal antibody therapies in lymphoma.
Teo EC; Chew Y; Phipps C
Crit Rev Oncol Hematol; 2016 Jan; 97():72-84. PubMed ID: 26318093
[TBL] [Abstract][Full Text] [Related]
25. Targeted Cancer Therapy with a Novel Anti-CD37 Beta-Particle Emitting Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma.
Repetto-Llamazares AH; Larsen RH; Patzke S; Fleten KG; Didierlaurent D; Pichard A; Pouget JP; Dahle J
PLoS One; 2015; 10(6):e0128816. PubMed ID: 26066655
[TBL] [Abstract][Full Text] [Related]
26. Targeting B-cell malignancies with the beta-emitting anti-CD37 radioimmunoconjugate
Maaland AF; Heyerdahl H; O'Shea A; Eiriksdottir B; Pascal V; Andersen JT; Kolstad A; Dahle J
Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2311-2321. PubMed ID: 31309259
[TBL] [Abstract][Full Text] [Related]
27. Evaluating antigen targeting and anti-tumor activity of a new anti-CD37 radioimmunoconjugate against non-Hodgkin's lymphoma.
Dahle J; Repetto-Llamazares AH; Mollatt CS; Melhus KB; Bruland OS; Kolstad A; Larsen RH
Anticancer Res; 2013 Jan; 33(1):85-95. PubMed ID: 23267131
[TBL] [Abstract][Full Text] [Related]
28. Effect of Number of Bifunctional Chelating Agents on the Pharmacokinetics and Immunoreactivity of 177Lu-labeled Rituximab: A Systemic Study.
Guleria M; Das T; Kumar C; Sharma R; Amirdhanayagam J; Sarma HD; Dash A
Anticancer Agents Med Chem; 2018; 18(1):146-153. PubMed ID: 28745238
[TBL] [Abstract][Full Text] [Related]
29. Brentuximab vedotin.
Ansell SM
Blood; 2014 Nov; 124(22):3197-200. PubMed ID: 25293772
[TBL] [Abstract][Full Text] [Related]
30. Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer.
Oostra DR; Macrae ER
Breast Cancer (Dove Med Press); 2014; 6():103-13. PubMed ID: 25114588
[TBL] [Abstract][Full Text] [Related]
31. 177Lu-DOTA-HH1, a novel anti-CD37 radio-immunoconjugate: a study of toxicity in nude mice.
Repetto-Llamazares AH; Larsen RH; Giusti AM; Riccardi E; Bruland ØS; Selbo PK; Dahle J
PLoS One; 2014; 9(7):e103070. PubMed ID: 25068508
[TBL] [Abstract][Full Text] [Related]
32. Advantage of lutetium-177 versus radioiodine immunoconjugate in targeted radionuclide therapy of b-cell tumors.
Repetto-Llamazares A; Abbas N; Bruland ØS; Dahle J; Larsen RH
Anticancer Res; 2014 Jul; 34(7):3263-9. PubMed ID: 24982330
[TBL] [Abstract][Full Text] [Related]
33. Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients.
Gopal AK; Tarantolo SR; Bellam N; Green DJ; Griffin M; Feldman T; Mato AR; Eisenfeld AJ; Stromatt SC; Goy A
Invest New Drugs; 2014 Dec; 32(6):1213-25. PubMed ID: 24927856
[TBL] [Abstract][Full Text] [Related]
34. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.
Flinn IW; van der Jagt R; Kahl BS; Wood P; Hawkins TE; Macdonald D; Hertzberg M; Kwan YL; Simpson D; Craig M; Kolibaba K; Issa S; Clementi R; Hallman DM; Munteanu M; Chen L; Burke JM
Blood; 2014 May; 123(19):2944-52. PubMed ID: 24591201
[TBL] [Abstract][Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
